The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

KB-52511     [(3-aminopyridin-2- yl)methylideneamino]thi...

Synonyms: 143621-35-6
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Triapine


High impact information on Triapine


Biological context of Triapine


Associations of Triapine with other chemical compounds


Gene context of Triapine


Analytical, diagnostic and therapeutic context of Triapine


  1. Synthesis and antitumor activity of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone. Liu, M.C., Lin, T.S., Sartorelli, A.C. J. Med. Chem. (1992) [Pubmed]
  2. PAN-811 (3-aminopyridine-2-carboxaldehyde thiosemicarbazone), a novel neuroprotectant, elicits its function in primary neuronal cultures by up-regulating Bcl-2 expression. Chen, R.W., Yao, C., Lu, X.C., Jiang, Z.G., Whipple, R., Liao, Z., Ghanbari, H.A., Almassian, B., Tortella, F.C., Dave, J.R. Neuroscience (2005) [Pubmed]
  3. Recognition and management of methemoglobinemia and hemolysis in a G6PD-deficient patient on experimental anticancer drug Triapine. Foltz, L.M., Dalal, B.I., Wadsworth, L.D., Broady, R., Chi, K., Eisenhauer, E., Kobayashi, K., Kollmannsburger, C. Am. J. Hematol. (2006) [Pubmed]
  4. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Giles, F.J., Fracasso, P.M., Kantarjian, H.M., Cortes, J.E., Brown, R.A., Verstovsek, S., Alvarado, Y., Thomas, D.A., Faderl, S., Garcia-Manero, G., Wright, L.P., Samson, T., Cahill, A., Lambert, P., Plunkett, W., Sznol, M., DiPersio, J.F., Gandhi, V. Leuk. Res. (2003) [Pubmed]
  5. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Yee, K.W., Cortes, J., Ferrajoli, A., Garcia-Manero, G., Verstovsek, S., Wierda, W., Thomas, D., Faderl, S., King, I., O'brien, S.M., Jeha, S., Andreeff, M., Cahill, A., Sznol, M., Giles, F.J. Leuk. Res. (2006) [Pubmed]
  6. In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Shao, J., Zhou, B., Zhu, L., Qiu, W., Yuan, Y.C., Xi, B., Yen, Y. Cancer Res. (2004) [Pubmed]
  7. In vitro and In vivo Radiosensitization Induced by the Ribonucleotide Reductase Inhibitor Triapine (3-Aminopyridine-2-Carboxaldehyde-Thiosemicarbazone). Barker, C.A., Burgan, W.E., Carter, D.J., Cerna, D., Gius, D., Hollingshead, M.G., Camphausen, K., Tofilon, P.J. Clin. Cancer Res. (2006) [Pubmed]
  8. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Murren, J., Modiano, M., Clairmont, C., Lambert, P., Savaraj, N., Doyle, T., Sznol, M. Clin. Cancer Res. (2003) [Pubmed]
  9. Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule. Feun, L., Modiano, M., Lee, K., Mao, J., Marini, A., Savaraj, N., Plezia, P., Almassian, B., Colacino, E., Fischer, J., MacDonald, S. Cancer Chemother. Pharmacol. (2002) [Pubmed]
  10. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) induces apoptosis in ovarian cancer cells. Alvero, A.B., Chen, W., Sartorelli, A.C., Schwartz, P., Rutherford, T., Mor, G. J. Soc. Gynecol. Investig. (2006) [Pubmed]
  11. A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Yen, Y., Margolin, K., Doroshow, J., Fishman, M., Johnson, B., Clairmont, C., Sullivan, D., Sznol, M. Cancer Chemother. Pharmacol. (2004) [Pubmed]
  12. Iron chelators as therapeutic agents for the treatment of cancer. Richardson, D.R. Crit. Rev. Oncol. Hematol. (2002) [Pubmed]
  13. Therapeutic potential of iron chelators in cancer therapy. Richardson, D.R. Adv. Exp. Med. Biol. (2002) [Pubmed]
  14. A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Shao, J., Zhou, B., Di Bilio, A.J., Zhu, L., Wang, T., Qi, C., Shih, J., Yen, Y. Mol. Cancer Ther. (2006) [Pubmed]
  15. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Chaston, T.B., Lovejoy, D.B., Watts, R.N., Richardson, D.R. Clin. Cancer Res. (2003) [Pubmed]
WikiGenes - Universities